Loading publications…
The last 5 uploaded publications
FKBP51 inhibits GSK3β and augments the effects of distinct psychotropic medications
Nils C. Gassen, Jakob Hartmann, Anthony S. Zannas, Anja Kretzschmar, Jürgen Zschocke, Giuseppina Maccarrone, Kathrin Hafner, Andreas Zellner, Lorenz Korbinian Kollmannsberger, Klaus V. Wagner, Divya Mehta, Stefan Kloiber, Christoph W. Turck, Susanne Lucae, George Chrousos, Herta Flor, Elisabeth B. Binder, Marcus Ising, Mathias V. Schmidt, Theo Rein (2015). FKBP51 inhibits GSK3β and augments the effects of distinct psychotropic medications. , 21(2), DOI: https://doi.org/10.1038/mp.2015.38.
Article74 days agoChaperoning epigenetics: FKBP51 decreases the activity of DNMT1 and mediates epigenetic effects of the antidepressant paroxetine
Nils C. Gassen, Gabriel R. Fries, Anthony S. Zannas, Jakob Hartmann, Jürgen Zschocke, Kathrin Hafner, Tania Carrillo‐Roa, Jessica Steinbacher, S. Nicole Preißinger, Lianne Hoeijmakers, Matthias Knop, Frank Weber, Stefan Kloiber, Susanne Lucae, George Chrousos, Thomas Carell, Marcus Ising, Elisabeth B. Binder, Mathias V. Schmidt, Joëlle Rüegg, Theo Rein (2015). Chaperoning epigenetics: FKBP51 decreases the activity of DNMT1 and mediates epigenetic effects of the antidepressant paroxetine. , 8(404), DOI: https://doi.org/10.1126/scisignal.aac7695.
Article74 days agoThe endocannabinoidome in neuropsychiatry: Opportunities and potential risks
Gerwyn Morris, Ken Walder, Stefan Kloiber, G. Paul Amminger, Michael Berk, Chiara C. Bortolasci, Michael Maes, Basant K. Puri, André F. Carvalho (2021). The endocannabinoidome in neuropsychiatry: Opportunities and potential risks. , 170, DOI: https://doi.org/10.1016/j.phrs.2021.105729.
Article49 days agoNeurodevelopmental pathways in bipolar disorder
Stefan Kloiber, Joshua D. Rosenblat, M. Ishrat Husain, Abigail Ortiz, Michael Berk, João Quevedo, Eduard Vieta, Michael Maes, Boris Birmaher, Jair C. Soares, André F. Carvalho (2020). Neurodevelopmental pathways in bipolar disorder. , 112, DOI: https://doi.org/10.1016/j.neubiorev.2020.02.005.
Article49 days agoThe endocannabinoidome in neuropsychiatry: Opportunities and potential risks
Gerwyn Morris, Ken Walder, Stefan Kloiber, G. Paul Amminger, Michael Berk, Chiara C. Bortolasci, Michael Maes, Basant K. Puri, André F. Carvalho (2021). The endocannabinoidome in neuropsychiatry: Opportunities and potential risks. , 170, DOI: https://doi.org/10.1016/j.phrs.2021.105729.
Article49 days ago